Innocan Pharma's Recent Breakthrough in CBD Research
Innocan Pharma Corporation, a leader in the pharmaceutical and biotechnology fields, has recently announced significant findings related to its LPT-CBD injection in Göttingen minipigs. This study, aiming to assess the pharmacokinetics and safety of this innovative product, is a crucial step in the company's ongoing mission to advance cannabinoid therapies.
The study, published in the esteemed journal Precision Nanomedicine, demonstrates that a single subcutaneous administration of LPT-CBD results in prolonged release and presents a favorable safety profile. This research offers a good translational model, paving the way for further studies and eventual clinical applications.
Corporate Updates and Leadership Changes
In addition to these promising research developments, Innocan has also undergone some notable changes within its leadership team. Effective July 1, 2025, Ron Mayron resigned from his positions as Executive Chairman and Director of the Company. However, he will continue to support Innocan as a Special Consultant for a further three months. Iris Bincovich, a current board member of the company, will temporarily step into the role of Chair until a permanent replacement is appointed.
Iris Bincovich expressed gratitude for Mayron's contributions, stating, "We are thankful to Ron, one of our founders, for his significant input over the years. His leadership has been invaluable, and we wish him all the best in his future ventures."
The company also announced the grant of 23,050,000 Restricted Share Units (RSUs) and 1,950,000 stock options to certain directors, officers, employees, and consultants, aimed at aligning the team's interests with those of its shareholders. The RSUs and options come with detailed milestone-based vesting conditions.
About Innocan
Innocan's innovative approach encompasses both pharmaceuticals and wellness solutions. The company is focused on developing a unique liposomal CBD delivery system that offers accurate dosing alongside prolonged effects for non-opioid pain management. Through its subsidiary, BI Sky Global Ltd., Innocan strives to enhance online sales of a broad range of self-care and beauty products, promoting healthier lifestyle choices for consumers.
As Innocan continues to pursue groundbreaking research and expand its operations, it remains committed to transparency and shareholder engagement. For more information, visit
Innocan Pharma's official website.
Forward-Looking Statements
As with all innovative ventures, Innocan's commitments carry inherent risks and uncertainties. The company advises stakeholders to stay informed through its public filings and updates, reflecting any potential changes in its regulatory landscape, market entry timelines, or product availability.
In conclusion, Innocan Pharma's recent advancements in CBD research coupled with significant corporate changes underline its position as a pioneering entity in the pharmaceutical industry. With a dedication to innovative solutions and strategic growth, Innocan continues to maintain momentum in the rapidly evolving landscape of cannabinoid therapies.